Furthermore, pharmacologically induced inhibition of BET protein with BET chemical degrader (dBET6) [24] selectively inhibits highly expressed ASXL3 subtype SCLC cells by decreasing viability, indicating the dependency of the oncogenic function of ASXL3/BRD4 axis in human SCLC. The gene discussed is BRD4; the disease is small cell lung carcinoma.